CT and MRI in monitoring response: state-of-the-art and future developments

Página do item simplificado
dc.contributor.authorD'Ippolito, Giuseppe [UNIFESP]
dc.contributor.authorTorres, Lucas Rios [UNIFESP]
dc.contributor.authorSaito Filho, Celso Fernando [UNIFESP]
dc.contributor.authorFerreira, R. M. [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-18T11:27:23Z
dc.date.available2018-06-18T11:27:23Z
dc.date.issued2011-12-01
dc.description.abstractThe present review is aimed at updating the reader with the current role of computed tomography (CT) and magnetic resonance imaging (MRI) in the evaluation of tumor response, contextualizing the imaging methods advantages and limitations. CT has been the most frequent and widely adopted diagnostic tool. The main advantages of such method include wide availability, high reproducibility, capability to contemporarily evaluate soft tissues, bone and lung parenchyma, besides being easy to perform. Its main limitation is related to the use of ionizing radiation. MRI has emerged as a feasible alternative to CT, particularly in patients with contraindications to the use of iodinated contrast agents, with advantages related to its high soft tissues contrast. The disadvantages are based on its operational complexity and the many technical variables involved which may influence and compromise the reproducibility and broad implementation of the method. New criteria for evaluation of tumor response have recently been proposed, contemplating lately developed drugs and therapeutic strategies that demand the utilization of functional parameters. In this context, the technological developments incorporated in the CT and MRI imaging techniques, such as perfusion analysis, diffusion studies (DW-RM) and MR spectroscopy (MRS), among others, have provided relevant information regarding the tumor response to targeted therapies, anticipating dimensional alterations and guiding physicians in the course of the treatment. Despite such developments, further efforts are needed to establish reproducible protocols, functional response criteria and time intervals for response evaluation in order to allow a definitive incorporation of these new technologies in the assessment of tumor response.en
dc.description.affiliationUniv Fed Sao Paulo, DDI, Escola Paulista Med, BR-04024002 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, DDI, Escola Paulista Med, BR-04024002 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent603-619
dc.identifierhttp://www.minervamedica.it/it/riviste/nuclear-med-molecular-imaging/articolo.php?cod=R39Y2011N06A0603
dc.identifier.citationQuarterly Journal Of Nuclear Medicine And Molecular Imaging. Turin: Edizioni Minerva Medica, v. 55, n. 6, p. 603-619, 2011.
dc.identifier.issn1824-4785
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/45172
dc.identifier.wosWOS:000301910700003
dc.language.isoeng
dc.publisherEdizioni Minerva Medica
dc.relation.ispartofQuarterly Journal Of Nuclear Medicine And Molecular Imaging
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTomography, X-ray computeden
dc.subjectMagnetic resonance imagingen
dc.subjectMedical oncologyen
dc.titleCT and MRI in monitoring response: state-of-the-art and future developmentsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos